MIRL

(redirected from CD59)
Also found in: Medical, Wikipedia.

MIRL

Meet in real life
References in periodicals archive ?
Transcription analysis of 44 CD genes was also carried out, indicating 24 CD genes (CD3E, CD244, CD69, CD247, CD40L, CD38, CD5L, CD44, CD5, CD83, CD163L1, CD36, CD14, CD28, CD200R1A, CD40, CD59, CD200, CD4, CD2, CD72, CD180, CD79B, and CD93) to be markedly increased by 2.
Because of its MOA involving the complement system, a mechanism potentially conserved across numerous disease conditions involving the immune system, its potential is also being explored in dozens of investigator-initiated trials for other conditions, including kidney transplantation, macular degeneration, CD59 deficiency, dense deposit disease and C3 nephropathy, and cold agglutinin disease.
Our own cells contain CD59, a membrane-anchored protein that protects us from complement-mediated damage by preventing assembly of a functional MAC.
HIV is able to incorporate a key protein in that self-protection mechanism, CD59, and by doing so makes itself appear to be one of the body's normal cells, not an infective agent.
CD59, a membrane bound complement regulatory protein prevents MAC formation by inhibiting the incorporation of C9 (8).
Toronto, Canada), a biotechnology company discovering and developing the next wave of antibody therapeutics, announced that new findings have been presented from its Trop-2 and CD59 antibody programs.
Individual chapter topics include the building blocks of the complement system, the classical pathway C1 complex, structure-function relationships in CD59, and cyclic antagonists of human C5a receptors.
The C8a subunit contains distinct binding sites for C8b, C8g, C9, and the complement regulatory protein CD59.
Pig hearts that display human complement inhibitors called CD59 and DAF can survive for more than 30 hours in baboons; unmodified organs last about an hour, reported investigators from Duke Medical Center and Nextran, a biotech firm in Princeton, N.
EXPLORE (EXamination of PNH, by Level Of CD59 on REd and white blood cells) is the first large multicenter study to determine the frequency of PNH cells in these patient populations using a central laboratory conducting a high sensitivity test for PNH cells.
The development of [alpha]1,3Gal deficient pigs expressing human complement regulatory proteins such as hDAF, MCP, and CD59 is necessary to overcome hyperacute rejection of pig organs transplanted into non-human primates by gene targeting technology.